Person in charge
Jean-Marie Dupret
Jean-Marie Dupret
To address the biological basis of pharmacogenomics. The main mechanisms of biotransformation of xenobiotics and the impact of these processes on the risk of adverse drug reactions and the occurrence of cancers are also presented.
Basics of pharmacogenomics, genetic polymorphisms
Enzymes and metabolism of xenobiotics
Xenobiotic receptors
Adverse drug reactions
Metabolism of carcinogens and cancers
Analysis of scientific articles
Arylamine N-acetyltransferase,
a major enzyme in the metabolism of xenobiotics,
with pharmacogenomic properties